WuXi Biologics (Cayman) Akcia Analýza akcií | Cena akcií | Novinky | 2269.HK | KYG970081173 | A2QJCN

Dátum	WuXi Biologics (Cayman) Cena akcie
17. 4. 2025	19,27 undefined
16. 4. 2025	19,00 undefined
15. 4. 2025	19,99 undefined
14. 4. 2025	19,98 undefined
11. 4. 2025	18,75 undefined
10. 4. 2025	18,13 undefined
9. 4. 2025	17,51 undefined
8. 4. 2025	16,83 undefined
7. 4. 2025	17,23 undefined
3. 4. 2025	23,25 undefined
2. 4. 2025	24,48 undefined
1. 4. 2025	24,81 undefined
31. 3. 2025	25,23 undefined
28. 3. 2025	25,03 undefined
27. 3. 2025	26,03 undefined
26. 3. 2025	24,51 undefined
25. 3. 2025	24,19 undefined
24. 3. 2025	24,49 undefined

Dátum	WuXi Biologics (Cayman) Tržby	WuXi Biologics (Cayman) EBIT	WuXi Biologics (Cayman) Zisk
2030e	41,49 mld. undefined	0 undefined	7,90 mld. undefined
2029e	37,19 mld. undefined	9,74 mld. undefined	6,76 mld. undefined
2028e	32,05 mld. undefined	8,72 mld. undefined	6,27 mld. undefined
2027e	26,08 mld. undefined	7,21 mld. undefined	6,16 mld. undefined
2026e	24,13 mld. undefined	6,35 mld. undefined	5,20 mld. undefined
2025e	20,81 mld. undefined	5,40 mld. undefined	4,39 mld. undefined
2024	18,68 mld. undefined	5,14 mld. undefined	3,36 mld. undefined
2023	17,03 mld. undefined	4,15 mld. undefined	3,40 mld. undefined
2022	15,27 mld. undefined	4,56 mld. undefined	4,42 mld. undefined
2021	10,29 mld. undefined	3,31 mld. undefined	3,39 mld. undefined
2020	5,61 mld. undefined	1,64 mld. undefined	1,69 mld. undefined
2019	3,98 mld. undefined	1,06 mld. undefined	1,01 mld. undefined
2018	2,53 mld. undefined	696,82 mil. undefined	630,59 mil. undefined
2017	1,62 mld. undefined	438,92 mil. undefined	252,63 mil. undefined
2016	989,03 mil. undefined	230,05 mil. undefined	141,10 mil. undefined
2015	557,04 mil. undefined	61,40 mil. undefined	44,51 mil. undefined
2014	331,85 mil. undefined	51,57 mil. undefined	41,98 mil. undefined

	Tržby	EBIT	Zisk
2014	331,85 mil. CNY	51,57 mil. CNY	41,98 mil. CNY
2015	557,04 mil. CNY	61,40 mil. CNY	44,51 mil. CNY
2016	989,03 mil. CNY	230,05 mil. CNY	141,10 mil. CNY
2017	1,62 mld. CNY	438,92 mil. CNY	252,63 mil. CNY
2018	2,53 mld. CNY	696,82 mil. CNY	630,59 mil. CNY
2019	3,98 mld. CNY	1,06 mld. CNY	1,01 mld. CNY
2020	5,61 mld. CNY	1,64 mld. CNY	1,69 mld. CNY
2021	10,29 mld. CNY	3,31 mld. CNY	3,39 mld. CNY
2022	15,27 mld. CNY	4,56 mld. CNY	4,42 mld. CNY
2023	17,03 mld. CNY	4,15 mld. CNY	3,40 mld. CNY
2024	18,68 mld. CNY	5,14 mld. CNY	3,36 mld. CNY
2025e	20,81 mld. CNY	5,40 mld. CNY	4,39 mld. CNY
2026e	24,13 mld. CNY	6,35 mld. CNY	5,20 mld. CNY
2027e	26,08 mld. CNY	7,21 mld. CNY	6,16 mld. CNY
2028e	32,05 mld. CNY	8,72 mld. CNY	6,27 mld. CNY
2029e	37,19 mld. CNY	9,74 mld. CNY	6,76 mld. CNY
2030e	41,49 mld. CNY	0 CNY	7,90 mld. CNY

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	2030e
0,33	0,56	0,99	1,62	2,53	3,98	5,61	10,29	15,27	17,03	18,68	20,81	24,13	26,08	32,05	37,19	41,49
-	68,28	77,56	63,60	56,61	57,18	40,90	83,36	48,38	11,57	9,63	11,42	15,97	8,06	22,92	16,04	11,56
37,16	32,32	39,33	40,79	40,13	41,63	45,12	46,92	44,04	40,08	40,96	36,76	31,70	29,34	23,87	20,57	18,44
0,12	0,18	0,39	0,66	1,02	1,66	2,53	4,83	6,72	6,83	7,65	0	0	0	0	0	0
0,04	0,04	0,14	0,25	0,63	1,01	1,69	3,39	4,42	3,40	3,36	4,39	5,20	6,16	6,27	6,76	7,90
-	7,32	220,45	78,72	150,00	60,79	66,63	100,71	30,46	-23,10	-1,27	30,75	18,55	18,34	1,90	7,75	16,88
0,96	2,89	2,89	3,48	3,94	4,00	4,21	4,42	4,38	4,35	4,23	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

0,01	0,16	0,17	2,06	4,08	6,75	8,48	11,13	8,71	11,24	10,71
0,13	0,19	0,29	0,31	0,80	1,37	2,36	3,26	5,14	6,15	6,43
0,03	0,09	0,13	0,30	0,30	0,40	0,76	1,59	0,98	0,63	0,03
0,06	0,15	0,20	0,34	0,23	0,40	1,08	1,69	2,28	1,77	1,52
0,00	0,01	0,04	0,02	0,33	0,75	1,52	1,86	1,35	1,41	4,88
0,23	0,60	0,83	3,03	5,75	9,67	14,20	19,53	18,47	21,20	23,57
0,40	0,75	1,15	1,78	2,90	6,80	12,87	19,76	25,92	29,94	28,44
0	0	0	0,02	0,19	0,45	1,07	2,20	2,71	2,93	2,40
0	0	0	0	0	0	87,67	124,49	109,17	165,50	85,67
0	0	0	0	331,81	415,85	391,86	600,65	548,78	511,83	442,37
0	0	0	0	0	0,19	0,19	1,53	1,53	1,53	1,53
2,67	1,61	2,37	18,23	219,97	80,61	150,48	289,21	281,45	296,47	511,10
0,41	0,76	1,16	1,82	3,65	7,93	14,76	24,50	31,09	35,38	33,40
0,64	1,36	1,98	4,85	9,39	17,60	28,96	44,03	49,56	56,58	56,98

0	0	158,00	192,00	202,00	214,00	225,00	235,00	233,00	235,00	226,00
0	0	0	3,44	6,65	10,26	15,95	27,04	22,10	24,49	0
0,37	0,15	0,27	0,59	1,33	2,51	4,41	8,23	13,58	17,61	41,82
0	0	0	0	11,80	12,59	211,98	-449,33	-547,49	-735,42	0
0	0	0	0	0	0	-2,69	-32,51	-92,24	-113,04	0
0,37	0,15	0,27	4,02	7,99	12,78	20,56	34,80	35,05	41,25	41,82
0,15	0,27	0,11	0,14	0,22	0,19	0,65	0,62	0,79	3,59	2,78
4,28	37,27	56,34	85,24	142,16	257,04	500,99	830,05	970,36	793,33	0
0,05	0,44	0,41	0,58	0,96	1,90	2,52	4,58	6,08	5,28	3,22
0,05	0,46	0,18	0	0	0,51	0,77	2,12	0	0	0
0	0	0,05	0	0	0,03	0,06	0,10	1,47	0,73	2,62
0,26	1,20	0,80	0,80	1,32	2,87	4,50	8,26	9,32	10,39	8,62
0	0	0,90	0	0	1,66	2,50	2,07	2,95	3,83	2,32
0	0	5,49	6,82	2,68	24,73	180,89	124,21	132,08	122,54	97,31
3,95	8,79	12,56	19,71	77,49	148,89	880,95	876,73	949,46	969,23	460,47
0,00	0,01	0,91	0,03	0,08	1,83	3,57	3,07	4,03	4,92	2,88
0,26	1,21	1,71	0,82	1,40	4,71	8,06	11,33	13,35	15,31	11,50
0,63	1,36	1,98	4,85	9,39	17,49	28,63	46,12	48,40	56,56	53,32

2014	2015	2016	2017	2018	2019	2020	2021	2022
0,05	0,07	0,18	0,30	0,74	1,13	1,97	3,99	5,36
42,00	57,00	93,00	87,00	141,00	221,00	303,00	481,00	800,00
0	0	0	0	0	0	0	0	0
-77,00	-43,00	-253,00	-157,00	-297,00	-294,00	-461,00	-1 313,00	-1 560,00
7,00	28,00	66,00	126,00	180,00	154,00	73,00	269,00	943,00
2,00	2,00	30,00	36,00	0	49,00	82,00	83,00	108,00
2,00	3,00	47,00	43,00	52,00	78,00	94,00	349,00	585,00
0,02	0,11	0,08	0,36	0,76	1,21	1,88	3,43	5,54
-51,00	-334,00	-428,00	-670,00	-1 673,00	-3 234,00	-6 024,00	-6 523,00	-5 868,00
-50,00	-336,00	-421,00	-2 213,00	-416,00	-4 493,00	-7 216,00	-9 601,00	-5 908,00
0	-0,00	0,01	-1,54	1,26	-1,26	-1,19	-3,08	-0,04
0	0	0	0	0	0	0	0	0
0	-0,00	0,89	-0,90	0	1,89	0,82	-0,15	-0,30
0	0	0	3,57	3,21	3,53	5,58	8,46	-2,80
0,03	0,38	0,33	2,23	3,21	5,41	6,57	8,21	-2,59
30,00	381,00	-560,00	-440,00	0	-8,00	159,00	-104,00	507,00
0	0	0	0	0	0	0	0	0
0,00	0,15	0,01	0,33	3,58	2,12	0,89	1,91	-2,61
-29,54	-227,21	-346,96	-310,32	-912,23	-2 026,58	-4 143,50	-3 091,86	-326,72
0	0	0	0	0	0	0	0	0

WuXi Biologics (Cayman) Hrubá marža	WuXi Biologics (Cayman) Marža zisku	WuXi Biologics (Cayman) EBIT marža	WuXi Biologics (Cayman) Marža zisku
2030e	40,97 %	0 %	19,04 %
2029e	40,97 %	26,18 %	18,17 %
2028e	40,97 %	27,21 %	19,57 %
2027e	40,97 %	27,64 %	23,61 %
2026e	40,97 %	26,30 %	21,56 %
2025e	40,97 %	25,94 %	21,09 %
2024	40,97 %	27,50 %	17,97 %
2023	40,08 %	24,35 %	19,96 %
2022	44,04 %	29,85 %	28,95 %
2021	46,93 %	32,16 %	32,93 %
2020	45,13 %	29,31 %	30,09 %
2019	41,64 %	26,66 %	25,45 %
2018	40,16 %	27,49 %	24,88 %
2017	40,80 %	27,11 %	15,61 %
2016	39,34 %	23,26 %	14,27 %
2015	32,44 %	11,02 %	7,99 %
2014	37,14 %	15,54 %	12,65 %

	Hrubá marža	EBIT marža	Marža zisku
2014	37,14 %	15,54 %	12,65 %
2015	32,44 %	11,02 %	7,99 %
2016	39,34 %	23,26 %	14,27 %
2017	40,80 %	27,11 %	15,61 %
2018	40,16 %	27,49 %	24,88 %
2019	41,64 %	26,66 %	25,45 %
2020	45,13 %	29,31 %	30,09 %
2021	46,93 %	32,16 %	32,93 %
2022	44,04 %	29,85 %	28,95 %
2023	40,08 %	24,35 %	19,96 %
2024	40,97 %	27,50 %	17,97 %
2025e	40,97 %	25,94 %	21,09 %
2026e	40,97 %	26,30 %	21,56 %
2027e	40,97 %	27,64 %	23,61 %
2028e	40,97 %	27,21 %	19,57 %
2029e	40,97 %	26,18 %	18,17 %
2030e	40,97 %	0 %	19,04 %

Dátum	WuXi Biologics (Cayman) Tržby na akciu	WuXi Biologics (Cayman) EBIT na akciu	WuXi Biologics (Cayman) Zisk na akciu
2030e	10,10 undefined	0 undefined	1,92 undefined
2029e	9,05 undefined	0 undefined	1,65 undefined
2028e	7,80 undefined	0 undefined	1,53 undefined
2027e	6,35 undefined	0 undefined	1,50 undefined
2026e	5,87 undefined	0 undefined	1,27 undefined
2025e	5,06 undefined	0 undefined	1,07 undefined
2024	4,42 undefined	1,22 undefined	0,79 undefined
2023	3,92 undefined	0,95 undefined	0,78 undefined
2022	3,49 undefined	1,04 undefined	1,01 undefined
2021	2,33 undefined	0,75 undefined	0,77 undefined
2020	1,33 undefined	0,39 undefined	0,40 undefined
2019	1,00 undefined	0,27 undefined	0,25 undefined
2018	0,64 undefined	0,18 undefined	0,16 undefined
2017	0,47 undefined	0,13 undefined	0,07 undefined
2016	0,34 undefined	0,08 undefined	0,05 undefined
2015	0,19 undefined	0,02 undefined	0,02 undefined
2014	0,34 undefined	0,05 undefined	0,04 undefined

	Tržby na akciu	EBIT na akciu	Zisk na akciu
2014	0,34 CNY	0,05 CNY	0,04 CNY
2015	0,19 CNY	0,02 CNY	0,02 CNY
2016	0,34 CNY	0,08 CNY	0,05 CNY
2017	0,47 CNY	0,13 CNY	0,07 CNY
2018	0,64 CNY	0,18 CNY	0,16 CNY
2019	1,00 CNY	0,27 CNY	0,25 CNY
2020	1,33 CNY	0,39 CNY	0,40 CNY
2021	2,33 CNY	0,75 CNY	0,77 CNY
2022	3,49 CNY	1,04 CNY	1,01 CNY
2023	3,92 CNY	0,95 CNY	0,78 CNY
2024	4,42 CNY	1,22 CNY	0,79 CNY
2025e	5,06 CNY	0 CNY	1,07 CNY
2026e	5,87 CNY	0 CNY	1,27 CNY
2027e	6,35 CNY	0 CNY	1,50 CNY
2028e	7,80 CNY	0 CNY	1,53 CNY
2029e	9,05 CNY	0 CNY	1,65 CNY
2030e	10,10 CNY	0 CNY	1,92 CNY

	Počet akcií
2014	964,00 mil. Aktien
2015	2,89 mld. Aktien
2016	2,89 mld. Aktien
2017	3,48 mld. Aktien
2018	3,94 mld. Aktien
2019	4,00 mld. Aktien
2020	4,21 mld. Aktien
2021	4,42 mld. Aktien
2022	4,38 mld. Aktien
2023	4,35 mld. Aktien
2024	4,23 mld. Aktien
2025e	4,23 mld. Aktien
2026e	4,23 mld. Aktien
2027e	4,23 mld. Aktien
2028e	4,23 mld. Aktien
2029e	4,23 mld. Aktien
2030e	4,23 mld. Aktien

Dátum	Odhad EPS	EPS-Aktuálny	spravodajské štvrťrok
31. 12. 2021	0,36	0,35 (-1,96 %)	2021 Q4
30. 6. 2021	0,42	0,40 (-4,35 %)	2021 Q2

%	Meno	Akciové spoločnosti	Zmena	Dátum
14,21957 %	WuXi Biologics Holdings Limited	584 191 133	0	24. 6. 2024
2,73492 %	The Vanguard Group, Inc.	112 360 289	164 000	31. 1. 2025
2,46307 %	BlackRock Institutional Trust Company, N.A.	101 191 969	-2 316 000	8. 8. 2024
1,90066 %	Norges Bank Investment Management (NBIM)	78 085 783	10 518 199	31. 12. 2024
1,70747 %	Schroder Investment Management North America Inc.	70 149 000	0	31. 12. 2024
1,49859 %	Bosera Asset Management Co., Ltd.	61 567 500	23 077 500	30. 6. 2024
1,36115 %	GF Fund Management Co., Ltd.	55 921 000	23 267 500	30. 6. 2024
1,34990 %	Hang Seng Investment Management Ltd.	55 458 922	1 430 808	31. 1. 2025
1,34685 %	Schroder Investment Management (Hong Kong) Ltd.	55 333 500	13 660 500	31. 12. 2024
1,08086 %	Dimensional Fund Advisors, L.P.	44 405 500	6 852 500	31. 1. 2025
1,04382 %	State Street Global Advisors Asia Ltd.	42 883 950	168 021	31. 10. 2023
1,02914 %	BlackRock Asset Management Ireland Limited	42 280 877	-7 414 992	8. 8. 2024
1,00181 %	BlackRock Advisors (UK) Limited	41 157 865	-116 500	31. 1. 2025
0,75684 %	JP Morgan Asset Management	31 093 818	2 538 669	16. 5. 2024
0,74828 %	China Merchants Fund Management Co. Ltd.	30 742 086	23 280 814	30. 6. 2024
0,69070 %	China Asset Management Co., Ltd.	28 376 500	0	30. 9. 2024
0,68558 %	Nuveen LLC	28 166 135	7 764	31. 1. 2025
0,60737 %	Harvest Fund Management Co., Ltd.	24 953 000	-5 490 500	30. 6. 2024
0,53557 %	Invesco Advisers, Inc.	22 003 000	21 746 000	31. 12. 2024
0,53210 %	Hongde Fund Management Co., Ltd.	21 860 649	10 859 500	30. 6. 2024
0,52344 %	JPMorgan Asset Management (Asia Pacific) Limited	21 505 000	-174 639	16. 5. 2024
0,50914 %	Zhong Ou Asset Management Co., Ltd.	20 917 169	-10 948 000	30. 6. 2024
0,42792 %	Geode Capital Management, L.L.C.	17 580 506	8 500	31. 1. 2025
0,40850 %	China Asset Management (Hong Kong) Limited	16 782 594	695 319	30. 9. 2024
0,34537 %	Chen (Zhisheng)	14 189 015	-61 499	20. 11. 2024
0,31889 %	APG Asset Management N.V.	13 100 944	1 680 143	31. 12. 2023
0,30625 %	INVESCO Great Wall Fund Management Co. Ltd.	12 581 918	-12 240 500	30. 6. 2024
0,27958 %	BlackRock Investment Management (UK) Ltd.	11 486 195	7 710 195	7. 8. 2024
0,27458 %	Penghua Fund Management Co., Ltd.	11 280 685	2 684 500	30. 6. 2024
0,27153 %	UBS Asset Management (Hong Kong) Limited	11 155 500	-44 000	30. 9. 2024
0,26810 %	E Fund Management Co. Ltd.	11 014 500	-123 661 500	30. 6. 2024
0,23698 %	China Southern Asset Management Co. Ltd.	9 736 000	6 181 800	30. 6. 2024
0,23608 %	HSBC JinTrust Fund Management Co., Ltd.	9 699 037	4 458 532	30. 6. 2024
0,23433 %	HuaAn Fund Management Co., Ltd.	9 627 000	3 674 000	30. 6. 2024
0,22642 %	ICBC Credit Suisse Asset Management Co. Ltd.	9 302 165	-468 835	30. 6. 2024
0,21349 %	Templeton Asset Management Ltd.	8 770 845	21 000	31. 1. 2025
0,21204 %	Li (Ge)	8 711 500	2 645 000	24. 6. 2024
0,19782 %	Amundi Asset Management, SAS	8 127 000	-22 500	31. 1. 2025
0,19149 %	State Street Global Advisors (US)	7 867 226	-12 500	31. 1. 2025
0,18916 %	Franklin Templeton International Services SARL	7 771 267	0	31. 12. 2024
0,18265 %	UBS Asset Management (UK) Ltd.	7 503 810	45 500	31. 1. 2025
0,17590 %	Baillie Gifford & Co.	7 226 500	-48 500	31. 12. 2024
0,17518 %	Allianz Global Investors Asia Pacific Limited	7 197 000	0	31. 12. 2024
0,17461 %	Chautauqua Capital Management, LLC	7 173 662	209 733	31. 12. 2024
0,17453 %	BlackRock (Netherlands) B.V.	7 170 182	7 170 182	8. 8. 2024
0,16881 %	State Street Global Advisors (UK) Ltd.	6 935 190	-1 435	31. 1. 2025
0,16573 %	California Public Employees' Retirement System	6 808 811	-379 000	30. 6. 2023
0,15058 %	Royal London Asset Management Ltd.	6 186 500	-224 500	30. 11. 2024
0,14999 %	Huashang Fund Management Co., Ltd.	6 162 130	2 432 130	30. 6. 2024
0,14794 %	Aviva Investors Global Services Limited	6 077 879	32 001	31. 12. 2024
0,14791 %	Northern Trust Global Investments Limited	6 076 500	309 000	31. 12. 2024
0,13804 %	Baring Asset Management Ltd.	5 671 214	0	31. 1. 2025
0,13755 %	Barings (U.K.) Limited	5 651 000	0	30. 11. 2024
0,13548 %	Goldman Sachs Asset Management, L.P.	5 566 102	-5 991	31. 12. 2024
0,13362 %	HSBC Global Asset Management (UK) Limited	5 489 657	151 333	31. 12. 2024
0,13291 %	BlackRock (Singapore) Limited	5 460 467	62 910	31. 1. 2025
0,13268 %	PGGM Vermogensbeheer B.V.	5 451 013	2 637 716	31. 7. 2024
0,13099 %	Dimensional Fund Advisors, Ltd.	5 381 500	0	31. 12. 2024
0,12704 %	Bank of Communications Schroder Fund Management Co., Ltd.	5 219 328	-19 014 877	30. 6. 2024
0,11915 %	UBS Fund Management (Switzerland) AG	4 895 000	-79 500	31. 1. 2025
0,11765 %	Mediolanum International Funds Limited	4 833 500	2 008 500	30. 9. 2024
0,11421 %	Sands Capital Management, LLC	4 692 130	-6 137 010	31. 3. 2024
0,11413 %	Capital Research Global Investors	4 689 000	-37 500	31. 12. 2024
0,10486 %	Franklin Templeton Investment Management Ltd.	4 307 937	0	31. 10. 2024
0,10413 %	China Universal Asset Management Co., Ltd.	4 278 000	-9 283 700	30. 6. 2024
0,10332 %	DWS Investment GmbH	4 244 915	3 574	31. 1. 2025
0,10178 %	Charles Schwab Investment Management, Inc.	4 181 430	0	31. 1. 2025
0,09598 %	Fullgoal Fund Management Co., Ltd.	3 943 023	1 702 450	30. 6. 2024
0,09251 %	Mirae Asset Global Investments (Hong Kong) Limited	3 800 495	0	30. 9. 2024
0,08945 %	Amundi Japan Ltd.	3 675 000	76 500	31. 1. 2025
0,08918 %	Essence Fund Management Co., Ltd.	3 664 000	1 512 000	30. 6. 2024
0,08775 %	AEGON Investment Management B.V.	3 605 085	-8 317	31. 10. 2024
0,07947 %	First Sentier Investments (U.K.) Ltd	3 265 000	0	31. 12. 2024
0,07775 %	Huatai-PineBridge Fund Management Co., Ltd.	3 194 413	-3 699 190	30. 6. 2024
0,07563 %	UBS Asset Management (Switzerland)	3 107 000	0	31. 1. 2025
0,07479 %	Edmond de Rothschild Asset Management (France) S.A.	3 072 636	70 089	30. 11. 2024
0,07361 %	DWS Investments UK Limited	3 024 210	0	31. 1. 2025
0,06711 %	Pictet Asset Management Ltd.	2 757 068	0	31. 12. 2024
0,06540 %	Legal & General Investment Management Ltd.	2 686 841	0	31. 1. 2025
0,06179 %	ZhongGeng Fund Management Co., Ltd.	2 538 500	2 538 500	30. 6. 2024
0,06085 %	Franklin Templeton Sealand Fund Management Co., Ltd.	2 500 000	2 500 000	30. 6. 2024
0,05842 %	S-Bank Fund Management Ltd	2 400 000	0	31. 7. 2024
0,05623 %	An Zhong (AZ) Investment Management Hong Kong Ltd.	2 310 000	0	30. 9. 2024
0,05427 %	Florida State Board of Administration	2 229 500	-745 000	30. 6. 2024
0,05370 %	BOCI-Prudential Asset Management Ltd.	2 206 247	2 000	31. 7. 2024
0,05327 %	Yinhua Fund Management Co., Ltd.	2 188 500	1 037 000	30. 6. 2024
0,05023 %	Handelsbanken Kapitalförvaltning AB	2 063 500	-81 000	31. 1. 2025
0,04926 %	Tianhong Asset Management Co., Ltd.	2 023 716	30 003	30. 6. 2024
0,04888 %	Allspring Global Investments, LLC	2 008 000	0	31. 12. 2024
0,04708 %	California State Teachers Retirement System	1 934 338	-1 809 500	30. 6. 2024
0,04588 %	Bellevue Asset Management AG	1 885 000	150 000	31. 12. 2024
0,04568 %	Mellon Investments Corporation	1 876 900	-19 500	31. 1. 2025
0,04563 %	Guotai Asset Management Co., Ltd.	1 874 548	597 157	30. 6. 2024
0,04515 %	CSOP Asset Management Limited	1 854 847	-28 000	31. 1. 2025
0,04394 %	Zürcher Kantonalbank (Asset Management)	1 805 347	0	31. 12. 2024
0,04176 %	Franklin Advisers, Inc.	1 715 500	315 000	31. 1. 2025
0,04059 %	BlackRock Asset Management North Asia Limited	1 667 402	620 248	31. 12. 2024
0,03731 %	Mercer Global Investments Management Ltd	1 533 000	-867 500	31. 12. 2024
0,03366 %	HFT Investment Management Co., Ltd.	1 383 000	130 500	30. 6. 2024
0,03363 %	Schroder Investment Management Ltd. (SIM)	1 381 438	0	30. 11. 2024

Meno	Vzťah	Dvojtýždňová korelácia	Mesačná korelácia	Trojmesačná korelácia	Šesťmesačná korelácia	Jednoročná korelácia	Dvojročná korelácia
Amicus Therapeutics	DodávateľKlient	0,87	0,16	0,22	0,70	0,57	-0,19
ABL Bio	DodávateľKlient	0,80	0,69	0,39	0,04	-0,65	-0,76
Sino Biopharmaceutical	DodávateľKlient	0,80	0,47	0,69	0,78	0,87	-0,04
Legochem Biosciences	DodávateľKlient	0,73	0,82	0,23	0,60	0,65	0,10
AC Immune	DodávateľKlient	0,68	0,77	0,42	0,79	0,92	0,49
Oncorus	DodávateľKlient	0,67	0,35	0,46	0,91	0,92
Antengene Corp Rg	DodávateľKlient	0,65	0,09	0,54	0,90	0,92
Cullinan Oncology	DodávateľKlient	0,65	0,49	0,23	0,72	0,91
Vir Biotechnology	DodávateľKlient	0,60	0,08	-0,02	0,86	0,77	0,41
Citigroup	DodávateľKlient	0,44	0,25	0,35	0,59	0,80	0,76

What values and corporate philosophy does WuXi Biologics (Cayman) represent?

WuXi Biologics (Cayman) Inc represents a strong set of values and a clear corporate philosophy. The company is committed to enabling global partners to develop and manufacture biologics efficiently and cost-effectively. WuXi Biologics is driven by a customer-centric approach, providing integrated solutions and the highest quality services to meet the diverse needs of its clients. With a focus on innovation, WuXi Biologics embraces cutting-edge technologies and invests in state-of-the-art facilities to ensure world-class bio-manufacturing capabilities. This dedication to excellence, along with a commitment to collaboration and integrity, positions WuXi Biologics as a trusted and leading player in the biopharmaceutical industry.

In which countries and regions is WuXi Biologics (Cayman) primarily present?

WuXi Biologics (Cayman) Inc is primarily present in China, with its headquarters in Shanghai. However, the company also has a global presence, with operations and facilities in multiple countries and regions. These include the United States, Germany, Ireland, Singapore, and China's Suzhou, Wuxi, and Hangzhou cities. With its international reach, WuXi Biologics (Cayman) Inc is well-positioned to cater to the global demand for biologics development, manufacturing, and supply chain solutions.

What significant milestones has the company WuXi Biologics (Cayman) achieved?

WuXi Biologics (Cayman) Inc, a leading global open-access biologics technology platform company, has achieved significant milestones since its inception. The company has rapidly expanded its capabilities and established strategic partnerships with global pharmaceutical giants. WuXi Biologics has successfully developed and launched numerous innovative biologics products, providing customized and high-quality solutions to its clients. Moreover, the company has received numerous accolades and recognition for its outstanding performance and contributions to the biopharmaceutical industry. Through its dedication to innovation and commitment to excellence, WuXi Biologics (Cayman) Inc continues to revolutionize the biologics landscape and drive advancements in healthcare.

What is the history and background of the company WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) Inc, founded in 2011, is a leading global open-access Biologics technology platform company. It offers end-to-end solutions for biologics discovery, development, and manufacturing to support worldwide partners in advancing biologics through various stages of development. With state-of-the-art facilities and a team of experienced professionals, WuXi Biologics leverages its expertise in cell line development, process development, and biologics manufacturing to offer cost-effective and high-quality services. The company's commitment to innovation, quality, and customer satisfaction has propelled its rapid growth and success in the biopharmaceutical industry. WuXi Biologics (Cayman) Inc is dedicated to enabling global healthcare by providing access to biologics for patients worldwide.

Who are the main competitors of WuXi Biologics (Cayman) in the market?

The main competitors of WuXi Biologics (Cayman) Inc in the market include companies such as Lonza Group Ltd., Catalent Inc., and Samsung Biologics Co., Ltd.

In which industries is WuXi Biologics (Cayman) primarily active?

WuXi Biologics (Cayman) Inc primarily operates in the biopharmaceutical industry.

What is the business model of WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) Inc. operates as a global open-access biologics technology platform company. It provides a comprehensive range of services in discovery, development, and manufacturing of biologics. The company's business model focuses on offering end-to-end solutions to global pharmaceutical and biotech companies. WuXi Biologics offers integrated services encompassing cell line development, process development, analytical development, and biologics manufacturing, including clinical and commercial manufacturing. By providing high-quality and cost-effective solutions, WuXi Biologics has established itself as a leading player in the biologics industry, enabling its clients to accelerate their drug development programs and reduce manufacturing costs.

Aké P/E má WuXi Biologics (Cayman) 2025?

Pomer WuXi Biologics (Cayman) cena/zisk je 18,57.

Aké KUV má WuXi Biologics (Cayman) 2025?

Koeficient WuXi Biologics (Cayman) P/S je 3,92.

Aký AlleAktien kvalitatívny skóre má WuXi Biologics (Cayman)?

AlleAktien kvalitatívne skóre pre WuXi Biologics (Cayman) je 8/10.

Aká je výška tržieb spoločnosti WuXi Biologics (Cayman) 2025?

Tržby spoločnosti očakávaná WuXi Biologics (Cayman) sú 20,81 mld. CNY.

Aká je výška zisku spoločnosti WuXi Biologics (Cayman) 2025?

Zisk očakávaná WuXi Biologics (Cayman) je 4,39 mld. CNY.

Čo robí WuXi Biologics (Cayman)?

The company WuXi Biologics (Cayman) Inc is a worldwide leading provider of end-to-end solutions in the biopharmaceutical industry. The company specializes in the manufacturing of biological drugs and offers a wide range of services, from research and development to manufacturing and marketing of products. WuXi Biologics' business model is divided into three main areas: 1. Research and Development: The company offers a comprehensive range of services for biopharmaceutical research and development, including protein and antibody structure elucidation, biomarker identification, cell line development, and small molecule production. WuXi Biologics aims to support its customers in accelerating their research process, thereby shortening the timeframe for product availability in the market. 2. Manufacturing: WuXi Biologics is one of the world's largest providers of manufacturing services for biological drugs. The company has a broad range of technologies and capabilities to meet its customers' requirements, from non-clinical to commercial product manufacturing. WuXi Biologics' production facilities are certified by the FDA or EMA, and the company strives to meet the highest standards in production and compliance with quality controls. 3. Marketing and Distribution: WuXi Biologics also offers marketing and distribution services for biological drugs, including support in product launch and management of distribution networks. The company has an experienced team of industry analysts, market researchers, and sales experts who help customers maximize their market presence and increase profits. The products offered by WuXi Biologics include biologicals, small molecules, and sample preparation, such as antibodies, peptides, recombinant proteins, and oligonucleotides. The company also provides platform technologies such as CHO-S production, plasmid manufacturing, virus production, proteomic analysis, and clinical diagnostics. With its innovative technologies, wide range of services, and ability to collaborate with customers worldwide, WuXi Biologics has firmly established its reputation as a leading company in the biopharmaceutical industry.

Aká vysoká je WuXi Biologics (Cayman) dividenda?

WuXi Biologics (Cayman) vypláca dividendu vo výške 0 CNY rozdelenú do výplat počas roka.

Ako často vypláca WuXi Biologics (Cayman) dividendu?

Dividenda pre WuXi Biologics (Cayman) sa aktuálne nedá vypočítať alebo spoločnosť nevypláca dividendu.

Aká je WuXi Biologics (Cayman) ISIN?

ISIN spoločnosti WuXi Biologics (Cayman) je KYG970081173.

Čo je to WuXi Biologics (Cayman) WKN?

WKN spoločnosti WuXi Biologics (Cayman) je A2QJCN.

Aký je WuXi Biologics (Cayman) ticker?

Ticker spoločnosti WuXi Biologics (Cayman) je 2269.HK.

Akú dividendu platí WuXi Biologics (Cayman)?

V posledných 12 mesiacoch spoločnosť WuXi Biologics (Cayman) vyplatila dividendu vo výške . To zodpovedá dividendovému výnosu približne . Pre nadchádzajúcich 12 mesiacov bude pravdepodobne spoločnosť WuXi Biologics (Cayman) vyplácať dividendu 0 CNY.

Aká je dividendová výnosnosť spoločnosti WuXi Biologics (Cayman)?

Súčasný výnos z dividend spoločnosti WuXi Biologics (Cayman) je .

Kedy vypláca WuXi Biologics (Cayman) dividendu?

WuXi Biologics (Cayman) vypláca dividendu každý štvrťrok. Tá je vyplácaná v mesiacoch .

Ako istá je dividenda spoločnosti WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) platil každý rok počas posledných 0 rokov dividendu.

Aká vysoká je dividenda spoločnosti WuXi Biologics (Cayman)?

Na nasledujúcich 12 mesiacov sa očakávajú dividendy vo výške 0 CNY. To zodpovedá dividendovému výnosu 0 %.

V ktorom sektore sa nachádza WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) je priradený sektoru 'Zdravie'.

Wann musste ich die Aktien von WuXi Biologics (Cayman) kaufen, um die vorherige Dividende zu erhalten?

Aby ste obdržali poslednú dividendu vo výške 0 CNY od WuXi Biologics (Cayman) z dňa 20. 4. 2025, museli ste mať akciu v depozite pred ex-dňom 20. 4. 2025.

Kedy poslednýkrát WuXi Biologics (Cayman) vyplatil dividendu?

Posledná dividenda bola vyplatená 20. 4. 2025.

Aká bola dividenda spoločnosti WuXi Biologics (Cayman) v roku 2024?

V roku 2024 boli od WuXi Biologics (Cayman) 0 CNY vyplatené ako dividendy.

V akej mene vypláca WuXi Biologics (Cayman) dividendu?

Dividendy spoločnosti WuXi Biologics (Cayman) sú vyplácané v CNY.

Priame emisie	32 687
Nepriame emisie z nakúpenej energie	149 229
Nepriame emisie v rámci hodnotového reťazca	65 463,77
Emisie CO₂	181 916
Stratégia redukcie CO₂
Uhlená energia
Atómová energia
Pokúsy na zvieratách
Pelz & Leder
Pesticídy
Palmový olej
Tabak
Géntechnológia
Koncept klímy
Udržateľné lesníctvo
Recyklačné predpisy
Ekologické obaly
Nebezpečné látky
Spotreba a účinnosť paliva
Spotreba a efektívnosť vody

Podiel žien zamestnancov	53
Podiel žien v manažmente
Podiel ázijských zamestnancov
Podiel ázijského manažmentu
Podiel hispánskych/latinoamerických zamestnancov
Podiel hispánskeho/latinského manažmentu
Podiel zamestnancov čiernej pleti
Podiel čierneho manažmentu
Podiel bielych zamestnancov
Podiel bieleho vedenia
Dospelých obsah
Alkohol
obrana
strelne zbrane
Hazard
Vojenské zmluvy
Koncept ľudských práv
Koncept ochrany údajov
Ochrana práce a zdravia
katolícky

Udržateľnostná správa
Angažovanosť zainteresovaných strán
Spätné volacie pravidlá
Antimonopolné právo

Burza	WuXi Biologics (Cayman) Ticker
DÜSSELDORF	1FW2.DU
FRANKFURT	1FW2.F
HKSE	2269.HK
MNÍCHOV	1FW2.MU
PNK	WXIBF

WuXi Biologics (Cayman) Ticker	WuXi Biologics (Cayman) FIGI
2269:HK	BBG00GTY47H0
1FW2:GR	BBG00GXQDVD3
1FW2:GF	BBG00GXQDVF1
1FW2:GD	BBG00GXQDVG0
1FW2:GS	BBG00GXQDVJ7
1FW2:GM	BBG00GXQDVK5
1FW2:GB	BBG00GXQDVL4
22691EUR:EO	BBG00GXY9799
22691EUR:XH	BBG00GXY97D4
22691EUR:XF	BBG00GXY97G1
22691EUR:XE	BBG00GXY97J8
22691EUR:XJ	BBG00GXY97K6
22691EUR:XL	BBG00GXY97L5
22691EUR:XG	BBG00GXY97M4
22691EUR:XO	BBG00GXY97N3
22691EUR:XA	BBG00GXY97T7
22691EUR:E1	BBG00GXY97V4
22691EUR:XT	BBG00GXY97W3
22691EUR:XW	BBG00GXY97X2
22691EUR:XU	BBG00GXY97Y1
22691EUR:XV	BBG00GXY97Z0
22691EUR:EU	BBG00GXY9815
2269:H2	BBG00HMKDMC7
2269:H1	BBG00HMKF104
WXIBF:US	BBG00HW3DBG4
WXIBF:PQ	BBG00HW3DBV7
WXIBF:UV	BBG00HW3DBW6
22691EUR:XX	BBG00JN8MQX7
2269N:L3	BBG00JRFL1G2
2269N:B3	BBG00JRFRRW1
2269N:PO	BBG00JRFXBK2
22691HKD:EO	BBG00JRGLFK4
22691HKD:XH	BBG00JRGLFN1
22691HKD:XF	BBG00JRGLFQ8
22691HKD:XE	BBG00JRGLFS6
22691HKD:XJ	BBG00JRGLFT5
22691HKD:XL	BBG00JRGLFV2
22691HKD:XG	BBG00JRGLFW1
22691HKD:XO	BBG00JRGLFX0
22691HKD:XA	BBG00JRGLG22
22691HKD:E1	BBG00JRGLG31
22691HKD:XT	BBG00JRGLG40
22691HKD:XW	BBG00JRGLG59
22691HKD:XU	BBG00JRGLG68
22691HKD:XV	BBG00JRGLG77
22691HKD:XM	BBG00JRGLG86
22691HKD:XQ	BBG00JRGLGB2
22691HKD:XX	BBG00JRGLGC1
22691HKD:XZ	BBG00JRGLGD0
22691HKD:EU	BBG00JRGLGG7
1FW:TH	BBG00L2RGBR0
22691HKD:X2	BBG00Q6SHJ59
1FW2:GZ	BBG00SSL1SB6
22691EUR:EP	BBG00SSQ7DN9
22691EUR:EZ	BBG00SSQ7DQ6
1FW2:QT	BBG00WR8TN37
2963N:L1	BBG00YB09YT7
2269N:MM	BBG00YG35MP0
2269N:MF	BBG00YG35MQ9
2269N:MU	BBG00YG35MR8
22691USD:EO	BBG00Z6CPDN8
22691USD:XH	BBG00Z6CPDR4
22691USD:XF	BBG00Z6CPDT2
22691USD:XE	BBG00Z6CPDW8
22691USD:XJ	BBG00Z6CPDX7
22691USD:XL	BBG00Z6CPDY6
22691USD:XG	BBG00Z6CPDZ5
22691USD:XO	BBG00Z6CPF08
22691USD:XA	BBG00Z6CPF44
22691USD:XT	BBG00Z6CPF62
22691USD:XW	BBG00Z6CPF71
22691USD:XU	BBG00Z6CPF80
22691USD:XV	BBG00Z6CPFB6
22691USD:XM	BBG00Z6CPFC5
22691USD:EU	BBG00Z6CPFL5
1FW2:LA	BBG018H9J6S9
1FW2:LU	BBG018J357J3

Urob najlepšie investície svojho života

Cena

Cena

Ticker2269.HK

ISINKYG970081173

WKNA2QJCN

WuXi Biologics (Cayman) Cena akcie

Kurs

Prehľad

Funkcia Intraday

Celkový výnos a relatívna zmena ceny

Interpretácia a investovanie

WuXi Biologics (Cayman) História kurzu

WuXi Biologics (Cayman) Akcia Obrat, EBIT, Zisk KYG970081173 · A2QJCN

Tržby, Zisk & EBIT

Porozumenie tržbám, EBIT a príjmu

Ročná analýza a porovnania

Využitie očakávaní pre investície

Investičné vhľady

WuXi Biologics (Cayman) Tržby, zisk a história EBIT

WuXi Biologics (Cayman) Akcie - Kľúčové ukazovatele

GuV

Tržby a rast

Hrubá marža

EBIT a marža EBIT

Príjem a rast

Počet akcií v obehu

Interpretácia ročných porovnaní

Očakávania a prognózy

Bilancia

Porozumenie bilancii

Aktíva

Záväzky

Vlastné imanie

Analýza rok za rokom

Interpretácia dát

WuXi Biologics (Cayman) Akcie Marže KYG970081173 · A2QJCN

Marže

Počítať brutto maržu

Analýza marže EBIT

Pohľady na maržu tržieb

Interpretácia očakávaní

Porovnávacia analýza

WuXi Biologics (Cayman) História marže

WuXi Biologics (Cayman) Akciový obrat, EBIT, zisk na akciu KYG970081173 · A2QJCN

Tržby, EBIT a Zisk na akciu

Tržby na akciu

EBIT na akciu

Príjem na akciu

Očakávané hodnoty

WuXi Biologics (Cayman) Tržby, zisk a EBIT na akciu História

WuXi Biologics (Cayman) Akcia a analýza akcií

Urob najlepšie investície svojho života.

WuXi Biologics (Cayman) Hodnotenie podľa Fair Value

Fair Value

Porozumenie Fair Value

Príjmový Fair Value

Obratový Fair Value

Dividendový Fair Value

Očakávania a prognózy

Porovnávacia analýza

WuXi Biologics (Cayman) Hodnotenie podľa historického KGV, EBIT a KUV

Urob najlepšie investície svojho života.

WuXi Biologics (Cayman) Počet akcií KYG970081173 · A2QJCN

Tržby, EBIT a Zisk na akciu

Tržby na akciu

EBIT na akciu

Príjem na akciu

Očakávané hodnoty

WuXi Biologics (Cayman) Akcie rozdelené

Urob najlepšie investície svojho života.

WuXi Biologics (Cayman) Odhad ziskov

WuXi Biologics (Cayman) Prekvapenia zisku

Eulerpool ESG hodnotenie pre akciu WuXi Biologics (Cayman)

Eulerpool World ESG Rating (EESG©)

95/ 100

🌱 Environment

👫 Social

🏛️ Governance

Životné prostredie (Environment)

Ticker
2269.HK

ISIN
KYG970081173

WKN
A2QJCN